Search results
Showing 136 to 150 of 187 results for prostate cancer
Evidence-based recommendations on Memokath 051 Ureter stent for ureteric obstruction.
Robot-assisted surgery for soft tissue procedures: early value assessment (HTG742)
Early value assessment (EVA) guidance on robot-assisted surgery for soft tissue procedures.
Evidence-based recommendations on the EOS 2D/3D imaging system for producing 2D and 3D images of the skeleton.
Denosumab for the prevention of osteoporotic fractures in postmenopausal women (TA204)
Evidence-based recommendations on denosumab (Prolia) for preventing osteoporotic fragility fractures in postmenopausal women.
Urinary tract infection (recurrent): antimicrobial prescribing (NG112)
This guideline sets out an antimicrobial prescribing strategy for preventing recurrent urinary tract infections in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.
This guideline has been updated and replaced by NICE guideline NG131.
This guidance has been updated and replaced by NICE guideline CG175.
We have moved interventional procedures guidance 119 to become HealthTech guidance 71. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
This evidence summary has been updated and replaced by NICE guideline NG131.
Care and support of people growing older with learning disabilities (NG96)
This guideline covers care and support for adults with learning disabilities as they grow older. It covers identifying changing needs, planning for the future, and delivering services including health, social care and housing. It aims to support people to access the services they need as they get older.
Diagnosing prostate cancer: PROGENSA PCA3 assay and Prostate Health Index (DG17)
This guideline has been updated and replaced by NICE guideline NG131.
Irreversible electroporation for treating prostate cancer (IPG768)
We have moved interventional procedures guidance 768 to become HealthTech guidance 688. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved Diagnostics guidance 54 to become HealthTech guidance 680. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Irreversible electroporation for treating prostate cancer (IPG572)
This guidance has been updated and replaced by NICE HealthTech guidance 688.
Hormone-sensitive metastatic prostate cancer: docetaxel (ESUOM50)
This evidence summary has been updated and replaced by NICE guideline NG131.